⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCNX News
Scienture Holdings, Inc. Common Stock
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
globenewswire.com
SCNX
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX
Form 8-K
sec.gov
SCNX
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
globenewswire.com
SCNX
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
globenewswire.com
SCNX
Form 8-K
sec.gov
NXNT
SCNX
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
globenewswire.com
SCNX
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
globenewswire.com
SCNX
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
globenewswire.com
SCNX